MX2019015210A - Dimeros de acidos grasos dicarboxilicos y sus derivados, a manera de patrones para cuantificar niveles en biomuestras. - Google Patents

Dimeros de acidos grasos dicarboxilicos y sus derivados, a manera de patrones para cuantificar niveles en biomuestras.

Info

Publication number
MX2019015210A
MX2019015210A MX2019015210A MX2019015210A MX2019015210A MX 2019015210 A MX2019015210 A MX 2019015210A MX 2019015210 A MX2019015210 A MX 2019015210A MX 2019015210 A MX2019015210 A MX 2019015210A MX 2019015210 A MX2019015210 A MX 2019015210A
Authority
MX
Mexico
Prior art keywords
gta
derivatives
biospecimens
standards
fatty acid
Prior art date
Application number
MX2019015210A
Other languages
English (en)
Inventor
Daniel E Levy
Dushmanthi Jayasinghe
Shawn Ritchie
Original Assignee
Med Life Discoveries Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Life Discoveries Lp filed Critical Med Life Discoveries Lp
Publication of MX2019015210A publication Critical patent/MX2019015210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporciona un compuesto de ácido del tracto gástrico (GTA) que tiene la estructura de la fórmula I, así como sales, ésteres, profármacos o derivados marcados de los mismos. Dichos compuestos de GTA se pueden utilizar para determinar los niveles de GTA de una muestra, para diagnosticar si un sujeto tiene o está en riesgo de desarrollar cáncer colorrectal o para aumentar los anticuerpos. Se describen anticuerpos, o fragmentos de los mismos, que se unen específicamente al GTA de la fórmula I, así como usos de dichos anticuerpos o fragmentos para determinar los niveles de GTA en una muestra o para diagnosticar si un sujeto padece o está en riesgo de desarrollar cáncer colorrectal. También se proporcionan kits que comprenden tales compuestos y/o anticuerpos de GTA. (ver Fórmula).
MX2019015210A 2017-06-15 2018-06-15 Dimeros de acidos grasos dicarboxilicos y sus derivados, a manera de patrones para cuantificar niveles en biomuestras. MX2019015210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520292P 2017-06-15 2017-06-15
PCT/CA2018/050729 WO2018227306A1 (en) 2017-06-15 2018-06-15 Dicarboxylic fatty acid dimers, and derivatives thereof, as standards for quantifying levels in biospecimens

Publications (1)

Publication Number Publication Date
MX2019015210A true MX2019015210A (es) 2020-08-17

Family

ID=64658907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015210A MX2019015210A (es) 2017-06-15 2018-06-15 Dimeros de acidos grasos dicarboxilicos y sus derivados, a manera de patrones para cuantificar niveles en biomuestras.

Country Status (10)

Country Link
US (1) US20200199038A1 (es)
EP (1) EP3638683A4 (es)
JP (1) JP7348649B2 (es)
KR (1) KR20200020801A (es)
CN (1) CN110741007A (es)
AU (1) AU2018286510B2 (es)
BR (1) BR112019026718A2 (es)
CA (1) CA3061768A1 (es)
MX (1) MX2019015210A (es)
WO (1) WO2018227306A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019253616A1 (en) * 2018-04-13 2020-11-05 Med-Life Discoveries Lp Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182169A1 (en) * 2005-09-12 2012-07-30 Phenomenome Discoveries Inc Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
CA2768086A1 (en) * 2009-07-29 2011-02-03 Phenomenome Discoveries Inc. Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
CA2797960A1 (en) * 2009-10-01 2011-04-07 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
WO2014186874A1 (en) * 2013-05-23 2014-11-27 Yyz Pharmatech, Inc. Methods and compositions for enzyme linked immuno and hybridization mass spectrometric assay

Also Published As

Publication number Publication date
KR20200020801A (ko) 2020-02-26
AU2018286510B2 (en) 2022-09-15
US20200199038A1 (en) 2020-06-25
EP3638683A4 (en) 2021-03-03
WO2018227306A1 (en) 2018-12-20
CA3061768A1 (en) 2018-12-20
CN110741007A (zh) 2020-01-31
BR112019026718A2 (pt) 2020-06-30
JP2020523324A (ja) 2020-08-06
AU2018286510A1 (en) 2019-12-19
JP7348649B2 (ja) 2023-09-21
EP3638683A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
MA34641B1 (fr) Anticorps anti-il-23
EP3578984A3 (en) Salivary biomarkers for oral cancer
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
WO2012112443A3 (en) Anti-mucin antibodies for early detection and treatment of pancreatic cancer
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112012007082A2 (pt) anticorpos que se ligam especificamente ao receptor do fator de crescimento epidérmico
BR112016027760A8 (pt) método de síntese de ph baixo de complexo de zinco-lisina
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2019015210A (es) Dimeros de acidos grasos dicarboxilicos y sus derivados, a manera de patrones para cuantificar niveles en biomuestras.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2017015036A (es) Conjugados fluorescentes.
WO2016100113A3 (en) Conjugates for assays for oxycodone and oxymorphone
BR112016030560A8 (pt) parceiros de ligação específicos para epímeros de vitamina d, anticorpo e método para separar uma vitamina d epimérica de uma amostra suspeita de conter uma vitamina d epimérica
UA109290U (uk) Спосіб діагностики розвитку остеопорозу
WO2015148825A3 (en) Methods and compositions for evaluating breast cancer patients
UA109291U (uk) Спосіб діагностики розвитку остеопорозу
UA109989U (uk) Спосіб діагностики розвитку остеопорозу
UA108307U (uk) Спосіб діагностики розвитку остеопорозу
UA110728U (uk) Спосіб діагностики розвитку остеопорозу
UA110679U (uk) Спосіб діагностики розвитку остеопорозу
UA109292U (uk) Спосіб діагностики розвитку остеопорозу
UA110006U (uk) Спосіб діагностики розвитку остеопорозу
UA110729U (uk) Спосіб діагностики розвитку остеопорозу
UA109473U (uk) Спосіб діагностики розвитку остеопорозу